Recognising the superior safety of direct oral anticoagulants (DOACs) over warfarin, and their equivalent or better efficacy in preventing strokes, is the first step in choosing a medication in patients with non-valvular atrial fibrillation (NVAF), according to Dr Christopher Hammett, interventional cardiologist at the Royal Brisbane and Women’s Hospital. “We need to focus on implementing ...
Choice of an anticoagulant in atrial fibrillation: interpreting the evidence
18 Apr 2018
Sponsored by Bayer Australia Pty Ltd